SYK - Stryker Corporation

NYSE - NYSE Delayed Price. Currency in USD
164.25
+0.70 (+0.43%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close163.55
Open163.84
Bid0.00 x 0
Ask0.00 x 0
Day's Range163.36 - 165.20
52 Week Range131.67 - 170.00
Volume2,041,696
Avg. Volume1,315,206
Market Cap61.284B
Beta0.48
PE Ratio (TTM)61.29
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.88 (1.19%)
Ex-Dividend Date2018-03-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • Here's Why You Should Invest in Stryker (SYK) Right Now
    Zacksyesterday

    Here's Why You Should Invest in Stryker (SYK) Right Now

    Stryker (SYK) gains from stellar performance of the flagship Mako platform; guidance solid.

  • Zacks.com highlights: Zebra Technologies, Stryker, Progressive, Interpublic Group and CBRE Group
    Zacks2 days ago

    Zacks.com highlights: Zebra Technologies, Stryker, Progressive, Interpublic Group and CBRE Group

    Zacks.com highlights: Zebra Technologies, Stryker, Progressive, Interpublic Group and CBRE Group

  • 4 MedTech Stocks to Keep in Good Books This Earnings Season
    Zacks3 days ago

    4 MedTech Stocks to Keep in Good Books This Earnings Season

    Considering the ageing population, changing market dynamics, upbeat consumer sentiment and increased business investments, the Medical-Device sector appears to be in pink of health.

  • 7 Stocks With Impressive Sales Growth to Keep an Eye On
    Zacks4 days ago

    7 Stocks With Impressive Sales Growth to Keep an Eye On

    Sales growth is an important indicator of a company's health and its ability to sustain its business.

  • Can Neurotechnology & Spine Drive Stryker (SYK) Q1 Earnings?
    Zacks4 days ago

    Can Neurotechnology & Spine Drive Stryker (SYK) Q1 Earnings?

    Stryker's (SYK) Neurotech business goes strong, VEXIM buyout likely to boost segment.

  • Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?
    Zacks5 days ago

    Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?

    Stryker's (SYK) acquisition-driven strategy is likely to boost Q1 results through the expansion of product offerings.

  • Stryker Loses 7.6% in a Month: What's Weighing It Down?
    Zacks12 days ago

    Stryker Loses 7.6% in a Month: What's Weighing It Down?

    Stryker's (SYK) declining margins and demand for healthcare products raise concern.

  • Investopedia14 days ago

    Top 3 Healthcare Stocks for 2018

    These three healthcare stocks were strong in 2017, and the upward trend may continue this year.

  • Johnson & Johnson’s Business Segments in 2017
    Market Realist16 days ago

    Johnson & Johnson’s Business Segments in 2017

    Analyzing Johnson & Johnson’s Stock and Valuations in March 2018

  • Analysts’ Recommendations on BD Stock in March 2018
    Market Realist22 days ago

    Analysts’ Recommendations on BD Stock in March 2018

    BDX's March 2018 Performance, Recommendations, and UpdatesAnalysts’ latest recommendations

  • 3D Printing in Vogue: 4 MedTech Stocks to Keep an Eye On
    Zacks23 days ago

    3D Printing in Vogue: 4 MedTech Stocks to Keep an Eye On

    3D printing lends a competitive edge to medical device manufacturers by enhancing efficiency and cutting down on processing time.

  • Where Stryker Corporation’s (NYSE:SYK) Earnings Growth Stands Against Its Industry
    Simply Wall St.28 days ago

    Where Stryker Corporation’s (NYSE:SYK) Earnings Growth Stands Against Its Industry

    In this article, I will take a look at Stryker Corporation’s (NYSE:SYK) most recent earnings update (31 December 2017) and compare these latest figures against its performance over the pastRead More...

  • See what the IHS Markit Score report has to say about Stryker Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about Stryker Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding SYK totaled $2.48 billion.

  • What Could Boost Haemonetics’ Revenues in Future Years
    Market Realistlast month

    What Could Boost Haemonetics’ Revenues in Future Years

    Haemonetics (HAE) expects its transfusion management business to grow at a compound annual growth rate (or CAGR) in the low to mid teens. Haemonetics has planned to opt for a key account strategy. The company aims to strengthen its worldwide presence by expanding its global sales team and partnering with other software vendors and players in this segment, like Helmer.

  • HAE Is Well Placed to Compete in Plasma Collection in Fiscal 2018
    Market Realistlast month

    HAE Is Well Placed to Compete in Plasma Collection in Fiscal 2018

    Haemonetics (HAE) is focused on initiating the commercial launch of its innovative NexSys PCS device coupled with its embedded firmware, NexLynk DMS, in 2H18. Although the combination of the NexSys PCS device and the NexLynk software is designed to result in a completely integrated and optimal bidirectional system, NexSys PCS supports an open architecture and can work with any other donor management software (or DMS). NexLynk software, however, has been designed to work optimally with NexSys PCS, and it thus eliminates the need for the translation of data between the device and the software.

  • Plasma Remains an Attractive Business for HAE
    Market Realistlast month

    Plasma Remains an Attractive Business for HAE

    In fiscal 2017, Haemonetics (HAE) earned almost 46% of its total revenue from its plasma franchise. The company has earned ~48.4% of its total revenue from its plasma franchise YTD (year-to-date) in fiscal 2018. Approximately 91% of the plasma segment’s total revenue in fiscal 2017 was attributable to the sale of disposables.

  • Plasma Continues to Drive Strong Growth for HAE in Fiscal 2018
    Market Realistlast month

    Plasma Continues to Drive Strong Growth for HAE in Fiscal 2018

    In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $113.1 million, a YoY (year-over-year) rise of ~4.1%. Haemonetics has earned revenue of nearly $324.4 million from the sale of its products in the plasma franchise YTD (year-to-date) in fiscal 2018, which reflects a YoY rise of ~4.7%. The franchise has reported organic revenue growth of close to 6% YTD in fiscal 2018, and it’s expected to continue witnessing robust growth owing to solid demand for drugs based on human plasma.

  • HAE Expects a Modest Net Profit Margin Expansion in Fiscal 2018
    Market Realistlast month

    HAE Expects a Modest Net Profit Margin Expansion in Fiscal 2018

    On its fiscal 3Q18 earnings conference call, Haemonetics (HAE) increased the guidance for its fiscal 2018 adjusted EPS (earnings per share) by ~$0.12 to the range $1.80–$1.90. Haemonetics has calculated this EPS guidance by assuming a positive impact from its overperformance in fiscal 3Q18 and a negative impact from its anticipated investments in fiscal 4Q18. Excluding the impact of its restructuring and turnaround expenses, the company expects $125 million worth of free cash flow in fiscal 2018.

  • HAE Is Expected to Report Flat Revenue Performance in Fiscal 2018
    Market Realistlast month

    HAE Is Expected to Report Flat Revenue Performance in Fiscal 2018

    Haemonetics (HAE) expects to report fiscal 2018 revenue in line with what it witnessed in fiscal 2017. The company also expects to witness 6% YoY revenue growth in its hospital business, lower than its previously projected revenue growth rate range of 7%–10%. Haemonetics, however, expects its blood center business to report a 7% YoY fall in fiscal 2018 revenue, which is at the lower end of its expectation of a fall of 7%–10%.

  • Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
    Zackslast month

    Orthopedic Device Market Gains Momentum: 3 Stocks in Focus

    The orthopedics market holds immense potential for investors who are keen on the healthcare space for long-term gains.

  • Why ConMed Is Expected to Report a Slight Rise in Its Net Profit Margin in 2018
    Market Realistlast month

    Why ConMed Is Expected to Report a Slight Rise in Its Net Profit Margin in 2018

    ConMed (CNMD) expects to witness the positive impact of around 0.5–1.0 percentage points on its fiscal 2018 adjusted gross margin, attributable to various cost-saving initiatives. ConMed has also projected an improvement of ~0.2–0.5 percentage points in its ratio of SG&A (selling, general, and administrative) expenses to total sales for fiscal 2018 on a YoY (year-over-year) basis. ConMed also expects its 2018 R&D (research and development)-to-sales ratio to be at the higher end of the projected range of 4.5%–5%.

  • Why ConMed Is Expected to Report Robust Revenue Growth in 2018
    Market Realistlast month

    Why ConMed Is Expected to Report Robust Revenue Growth in 2018

    ConMed (CNMD) expects to report revenue growth in the range of 5%–6.5% on a reported basis and in the range of 4.0%–5.0% on a CC (constant currency) basis for fiscal 2018. The company has projected a favorable top-line impact of 100–150 basis points, resulting from foreign exchange movements for fiscal 2018. In 2017, ConMed reported a ~4.3% YoY (year-over-year) rise in revenues on a CC basis, which would be in line with the average revenue growth in the medical technology industry.

  • ConMed and Peers in 2018: Analyst Recommendations
    Market Realistlast month

    ConMed and Peers in 2018: Analyst Recommendations

    Headquartered in Utica, New York, ConMed (CNMD) currently employs 3,100 people worldwide. In 4Q17, ConMed reported total sales close to $222.6 million, which represents a YoY (year-over-year) rise of ~7.9% on a CC (constant currency) basis and 9% on a reported basis, driven by the robust uptake of its products in the US and in international geographies. For fiscal 2017, ConMed reported total sales close to $796 million, which represents a YoY rise of ~4.3%, both on a CC and reported basis.